Melanoma Matters

Summary

Verbalizing punctuation for laughs...background wood noises ... and out of office replies get things started.

In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel record their first in a series of "Best of 2024" and review highlights from the ASCO Annual Meeting. They focus on 4 significant trials: NADINA, COMBI-AD, KEYNOTE 942, and RELATIVITY 048.

James & Sapna discuss the implications of these studies on the melanoma landscape, the importance of long-term follow-up data, and share some light-hearted moments about out-of-office messages.

Keywords

ASCO 2024, melanoma, NADINA trial, neoantigen therapy, checkpoint blockade, out of office messages, long-term follow-up, immunotherapy

Takeaways

Out-of-office messages can be creative and memorable.

The NADINA trial showed a high major pathologic response rate of 60%.

Patient inclusion and trial design in clinical trials can critically affect outcomes (COMBI-AD).

The KEYNOTE 942 trial demonstrated encouraging trends for overall survival.

Triplet checkpoint blockade shows promising PFS results (RELATIVITY 048).

Titles

ASCO 2024 Highlights: Melanoma Trials Reviewed

NADINA, COMBI-AD, KN 942, RELA 048

Chapters

00:00 Introduction and Icebreakers

06:24 ASCO 2024 Highlights: NADINA Trial

13:39 Long-Term Follow-Up: COMBI-AD Study

21:16 Individualized Neoantigen Therapy: KEYNOTE 942

30:23 Triplet Checkpoint Blockade: RELATIVITY 048

31:11 Fact Check Best of 2024: ASCO

31:16 FDA Guidelines on Phase 3 Trials (Listening Series)

In this episode we are calling VIBE - Voicing Interesting Bits from Everyone - we want to hear from YOU!

We've opened an email address to field your questions, concerns, feedback and input.

While we cannot answer specific patient case questions, this is a great forum to clarify any questions around the data. Our plan is to record an episode discussing the questions we receive.

[email protected]

Summary

In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin welcome surgical oncologist Mark Faries to discuss the evolution of surgical practices in melanoma, particularly focusing on sentinel lymph node biopsy and the implications of recent clinical trials. They explore the historical context of lymph node surgeries, the significance of nomograms in predicting patient outcomes, and the latest NCCN guidelines regarding clinic l stage II melanoma. They also delve into the emerging role of neoadjuvant therapies and the planned MSLT-3 trial, exploring the balance between effective treatment and minimizing surgical interventions. The

Takeaways

Keywords

melanoma, surgical oncology, lymph nodes, sentinel lymph node biopsy, MSLT trials, adjuvant therapy, nomograms, NCCN guidelines, neoadjuvant therapy, immune suppression

Titles

Navigating Melanoma: Insights from Surgical Oncology

The Evolution of Sentinel Lymph Node Surgery

Sound Bites

"No tumor is resistant to formaldehyde."

"Surgery is the gold standard."

"We need that staging information."

Chapters

00:00 Introduction and Welcome to Special Guest, Mark Faries

06:06 The Evolution of Lymph Node Surgery

09:07 MSLT Trials: Insights and Outcomes

11:59 Current Practices in Sentinel Lymph Node Biopsy

15:02 Adjuvant Therapy and Its Implications

21:09 NCCN Guidelines and Clinical Stage II Disease

24:19 MSLT-3: A New Era in Melanoma Surgery

26:52 The Role of Immune Suppression with Surgery

Summary

In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel welcome their first live guest, Toni Ribas. The conversation covers the evolution of melanoma treatments, the challenge of treatment resistance, and the importance of clinical trials. The episode emphasizes the need for continuous innovation and the importance of understanding the complexities of the immune system in cancer therapy.

Takeaways

Keywords

melanoma, oncology, immunotherapy, targeted therapy, clinical trials, resistance, checkpoint inhibitors, cancer treatment, patient care, medical research

Sound Bites

"We need to do clinical experimentation."

"We've democratized treatment of melanoma."

Chapters

00:00 Introduction of Guest Toni Ribas

03:29 Toni Ribas' Journey in Oncology

05:44 A Brief History of Melanoma Treatment Before it was Cool

08:26 Understanding Resistance in Melanoma Therapy

11:25 The Role of Targeted Therapy and Immunotherapy

14:35 Clinical Trials and Lessons Learned

17:47 Chasing Complete Responses in Melanoma

20:18 The Future of Melanoma Treatment

22:49 Conclusion and Reflections

Summary

In this episode of Melanoma Matters, James tells us about his path to oncology (thank you, Emma) via John Newsom-Davis, the Jeremy Bentham pub, and Hammersmith Hospital.

Later, hosts Sapna Patel and James Larkin discuss the COLUMBUS 7-year data of targeted therapy for metastatic melanoma - treatment efficacy, toxicity, and long-term patient management. They explore the nuances of treatment strategies, the importance of biomarkers, and the challenges of monitoring long-term patients on targeted therapies.

Takeaways

Time to next therapy is a valuable metric for assessing treatment success.

Long-term treatment decisions should consider patient quality of life.

Biomarkers are crucial for determining the duration of targeted therapy.

Compliance in clinical trials may not reflect real-world scenarios.

Monitoring for long-term toxicity is necessary for patients on extended therapy.

The combination of BRAF and MEK inhibitors may improve tolerability despite the COLUMBUS study showing a higher toxicity rate in the combination arm.

Congratulations to the European colleagues who led and executed this trial.

Keywords

BRAF MEK, targeted therapy, COLUMBUS study, melanoma, treatment efficacy, toxicity, long-term care, patient management

Titles

Exploring the COLUMBUS 7-Year Data

Oncology Journeys: Personal Stories and Insights

Sound Bites

"We need to know even the low-grade toxicities."

"There's nothing wrong with improving side effects."

"Kudos to our mainland European colleagues."

Chapters

00:00 Introduction

06:12 COLUMBUS 7-Year Overview

12:15 Historical context on study arms

17:55 Long-Term Treatment Considerations

21:29 Desperate... for a Biomarker

23:43 Any insights into development of CNS disease?

30:47 Fact Check for COLUMBUS 7-Year follow-up

32:50 Time to End of Next Line of Treatment in COLUMBUS (akin to PFS2)

35:32 Toxicity & Discontinuation Rate in COLUMBUS

Teaser: Find out Allison's favorite body part, had she been an orthopedic surgeon (and James' 2nd favorite.. from the movie Sleeper)

Summary

In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin welcome Dr. Allison Betof-Warner, Director of the Advanced Melanoma Program at Stanford University. The conversation explores Dr. Betof-Warner's journey into oncology, her passion for CrossFit, and the significant role of exercise in cancer prevention and treatment. They discuss the emerging field of exercise oncology, the importance of strength training for cancer patients, and the latest advancements in cellular therapy for melanoma, particularly in patients with brain metastases. Hot take: physical activity is a vital component of cancer treatment.

Keywords

melanoma, oncology, exercise oncology, cancer prevention, cellular therapy, CrossFit, strength training, TIL therapy, patient care, health and wellness

Takeaways

Exercise is crucial throughout the cancer journey, from prevention to treatment.

The field of exercise oncology is growing, focusing on the benefits of physical activity for cancer patients.

Strength training is now recommended for cancer patients to maintain function and prevent cachexia.

Patients should be encouraged to engage in regular physical activity, even during treatment.

Research shows that exercise can improve tumor vascular structure and enhance chemotherapy delivery.

The safety of exercise during cancer treatment has been increasingly supported by research.

Cellular therapy is a promising area of research for melanoma, especially in patients with brain metastases.

Patient education regarding exercise during treatment is important.

A multidisciplinary approach to cancer care, including physical therapy, is essential for optimizing patient outcomes.

Titles

The Role of Exercise in Cancer Treatment

Cellular Therapy in Melanoma with Brain Metastasis

Sound Bites

"I shifted the direction of my research, did my PhD in cancer research."

"Exercise spans the cancer journey."

"Exercise helps prevent cancer cachexia."

Chapters

00:00 Introduction

03:24 Allison's Journey to Oncology and CrossFit

06:32 The Intersection of Exercise and Cancer

09:33 Exercise Oncology: Benefits and Guidelines

19:22 Safety and Efficacy of TIL Therapy for CNS disease

25:22 Patient Exercise During Cell Therapy

Summary

Gulf oysters and FATE get a shoutout in this episode of Melanoma Matters. Hosts James Larkin and Sapna Patel discuss the ADAPT-IT study, focusing on adaptive dosing strategies in immunotherapy for melanoma. They explore the study's design, results, and implications for clinical practice, including the potential for reduced dosing based on early response assessments.

Keywords

ADAPT-IT study, immunotherapy, melanoma, adaptive dosing, clinical efficacy, treatment response, toxicity management, cancer research

Takeaways

The ADAPT-IT study explores adaptive dosing in immunotherapy.

68% of patients showed favorable anti-tumor effects after two doses.

Early response assessments can guide treatment decisions.

The study suggests that two doses may be sufficient for some patients.

There is potential for one dose to be effective in certain cases.

Reimbursement policies may influence treatment strategies.

Correlative studies provide insights into treatment efficacy.

Management of toxicity is crucial in immunotherapy.

The conversation highlights the importance of clinical intuition.

Future research may refine dosing strategies further.

Sound Bites

"Is two cycles enough?"

"68% had a favorable anti-tumor effect."

"Could one dose be enough?"

Chapters

00:00 Introduction to the ADAPT-IT Study

04:12 FATE v non-FATE

06:03 Clinical Implications of Early Response Assessment

09:02 Results and Efficacy of the Study

11:50 Discussion

14:18 Exploring the Role of LDH in Treatment Decisions

17:32 Correlative Studies and Future Directions

20:14 Toxicity and Management Strategies

22:58 Correlatives (ctDNA)

30:54 Bit of good news about NADINA

Summary

In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel engage with Bettina Ryll, founder of the Melanoma Patient Network Europe (MPNE). Bettina shares her personal journey from being a physician to becoming a patient advocate after her husband's battle with metastatic melanoma. The conversation explores the evolution of patient support networks, the challenges faced in healthcare systems, and complex adaptive systems. Bettina emphasizes the need for systemic change to improve patient access to treatments and highlights the importance of understanding the interconnectedness of healthcare, economics, and patient outcomes.

Keywords

melanoma, patient advocacy, healthcare systems, immunotherapy, patient networks, Bettina Ryll, MPNE, clinical trials, healthcare access, systemic change

Takeaways

Bettina Ryll founded MPNE after her husband's battle with melanoma.

Patient networks are crucial for sharing knowledge and support.

Understanding the healthcare system is key to advocating for patients.

Immunotherapy presents complex challenges that need addressing.

Systemic change is necessary for improving patient access to treatments.

The pharmaceutical landscape is influenced by economic factors.

Patients should not be treated as victims of their circumstances.

Action is often more effective than extensive planning.

Collaboration and community (and ferocious energy) are essential for driving change.

Sound Bites

"I just started explaining science."

"We are sentinels for issues."

"We must be standing for something."

Chapters

00:00 Introduction to Bettina Ryll

06:19 The Formation of Melanoma Patient Network Europe

11:51 Understanding Patient Needs and Systemic Issues

17:54 Challenges in Immunotherapy and Clinical Trials

23:47 Healthcare and Patient Access as Complex Adaptive Systems

29:25 The Role of Community and Collaboration in Change

SummaryIn this episode of Melanoma Matters, hosts James Larkin and Sapna Patel engage with Jedd Wolchok, a prominent figure in oncology, to discuss his journey into the field, the evolution of immunotherapy, particularly the Checkmate-067 trial, and the long-term outcomes for melanoma patients. The conversation highlights the importance of collaboration in clinical trials, the significance of understanding treatment decisions, and the future of melanoma treatment with a focus on biomarkers and patient follow-up. The discussion also reflects on the profound impact of Checkmate-067 on patient care and the oncology community.Keywordsmelanoma, immunotherapy, Checkmate-067, oncology, patient outcomes, long-term follow-up, biomarkers, cancer treatment, clinical trials, survivorshipTakeawaysJedd Wolchok's journey into oncology was influenced by family experiences with cancer.The Checkmate-067 trial was a pivotal moment in melanoma treatment.Collaboration among researchers is crucial for successful clinical trials.Long-term follow-up data from Checkmate-067 shows promising outcomes for patients.Understanding residual abnormalities in imaging is essential for treatment decisions.The need for biomarkers to assess immune system activation is critical.Patient follow-up strategies should be tailored to individual needs.The impact of Checkmate-067 extends beyond melanoma to other cancers.The evolution of immunotherapy has changed the landscape of cancer treatment.Mentorship and collaboration are key to advancing oncology research.TitlesReflections on a Career in OncologyThe Impact of Checkmate-067 on OncologySound Bites"This is something that we need to be doing.""We need to incorporate the symptomatic meaning.""Not every residual area of abnormality is cancer."Chapters00:00 Introduction to Melanoma Matters and Guest Background03:25 Journey into Oncology and Early Influences06:26 The Evolution of Immunotherapy: Checkmate-06709:14 The Significance of Phase One Trials12:25 Long-term Outcomes and Implications of Checkmate-06715:09 Understanding Treatment Responses and Patient Management18:06 The Future of Oncology: Biomarkers and Precision Medicine21:19 Survivorship and Patient Follow-up Strategies24:21 Reflections on the Impact of Checkmate-06727:24 Closing Thoughts and Acknowledgments

Summary

In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel welcome Dr. Andreas Schmitt to discuss various aspects of melanoma treatment, including the importance of supplementary data in clinical trial reports, the implications of the TRICOTEL study, and the role of PD-L1 as a biomarker. The conversation highlights the significance of peer review and academic collaboration in oncology, as well as the impact of regulatory decisions on patient treatment options. The episode concludes with a discussion on the findings of the republished TRICOTEL study and the importance of inquiry in medical practice.

Keywords

melanoma, oncology, clinical trials, PD-L1, TRICOTEL study, symptomatic brain metastasis, supplementary data, peer review, academic collaboration, cancer treatment, biomarkers

Takeaways

The importance of looking at supplementary data in clinical trials is a recurring theme in this podcast.

The TRICOTEL study revealed significant findings regarding treatment for symptomatic brain metastasis, but there was controversy over the coding of these patients as symptomatic.

Peer review and academic collaboration are crucial in addressing discrepancies in clinical data.

PD-L1 expression may not be a reliable biomarker for treatment decisions in melanoma.

Regulatory decisions can impact patient access to effective treatments.

The objective response rate in the TRICOTEL republication was lower than in the initial (retracted) report.

Inquiring and questioning data is an essential feature of an intrepid (F)ellow.

Continuous reading and inquiry are vital for oncologists to stay informed.

Sound Bites

"Why I'm an oncologist?"

"Look at the supplementaries!"

"We redesigned the SWOG S2000 study after the TRICOTEL presentation to drop the asymptomatic cohort."

Chapters

00:00 Introduction and Lighthearted Banter

00:30 Meet the Guests: Andreas Schmitt

01:34 Always read the Supplemental Appendix!

06:31 The TRICOTEL Controversy Unveiled

10:43 Symptomatic Cohort in TRICOTEL

18:35 Peer Review in Publications

20:20 Republication of the TRICOTEL data

22:08 Editorial(s) on PD-L1 as a Biomarker

32:38 Concluding Thoughts on PD-L1